Regulatory

53 articles in this category (Page 3 of 3)

TechnologyCloud ComputingRegulatory

MSFT 21-Day Outlook: Sideways Trend Expected Amid Mixed Sentiment and Regulatory Headwinds

Microsoft faces a sideways trajectory as strong fundamental growth is offset by cautious Azure guidance, surging AI CapEx, and a recent Japan FTC raid.

Feb 25, 2026MSFT

RegulatoryEarningsTechnical Analysis

ImmunityBio (IBRX) Faces Consolidation as Overbought Technicals Clash with Global Approval Euphoria

Despite securing global approvals and 700% revenue growth, IBRX is expected to trade sideways as an overbought RSI of 79.90 and severe cash burn cap near-term upside.

Feb 24, 2026IBRX

HealthcareEarningsRegulatory

BillionToOne (BLLN): Medicare Coverage and Upcoming Earnings Setup Potential Rebound

Recent Medicare coverage for Northstar Select and reiterated revenue guidance provide strong catalysts for BLLN ahead of its March 4 earnings, despite weak technical momentum.

Feb 23, 2026BLLN

regulatoryproductearnings

ImmunityBio (IBRX) 21-Day Outlook: Increase Expected Amidst Global ANKTIVA Approvals Despite Overbought Technicals

ImmunityBio's massive 700% revenue growth and new international ANKTIVA approvals signal upside potential, though overbought technicals and deep negative margins cap confidence.

Feb 23, 2026IBRX

TechnologyRegulatoryMarket Analysis

Apple Inc. (AAPL) 21-Day Outlook: Sideways Consolidation Amid Mixed Regulatory and AI Signals

AAPL is poised for sideways movement as strong fundamental cash flows clash with FTC regulatory warnings and delayed AI rollouts.

Feb 21, 2026AAPL